ArticleCancer communications (London, England)2022

KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.

Chengming Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.